January 2005, Volume 35 Number 1 , p 29 - 29
© 2005 Lippincott Williams & Wilkins, Inc. Volume 35(1) January 2005 p 29 Docetaxel approved for prostate cancer [DRUG NEWS: BREAST CANCER DRUG]
A mainstay for breast cancer treatment, docetaxel (Taxotere) has been approved by the FDA to treat prostate cancer too.
Given by injection in a regimen that includes prednisone, the drug may prolong the lives of men with advanced disease. In clinical trials, the treatment extended life for men with metastatic, hormone-refractory prostate cancer by about 2½ months, compared with a similar group receiving standard chemotherapy with mitoxantrone and prednisone.
Patients receive a docetaxel injection once every 3 weeks and prednisone daily. Possible adverse reactions include nausea, alopecia, bone marrow suppression, fluid retention, and peripheral neuropathy.
For more information, visit the FDA's Web site ...